Cancer Profiling and Pathways

1 post / 0 new
samm
samm's picture
Cancer Profiling and Pathways

I was kinda late with this one, but it might be of interest especially for those of you in the North California area.
Fifth Annual
Cancer Profiling and Pathways
February 25-27, 2009 | Moscone Convention Center | San Francisco, California

This year's event features comprehensive coverage on: 

INTEGRATING NEXT-GEN TECHNOLOGIES FOR RISK ASSESSMENT
EPIGENETIC AND MICRORNA: FINDING PATHWAYS TO TREATMENT 
EVALUATING CANCER TARGETS 
WHOLE GENOME EXPRESSION PROFILING 
MAPPING PATHWAYS AND IDENTIFYING THE INTERVENTION POINTS

Cancer Profiling and Pathways Keynotes: 

A Single Cell Based Understanding of Cancer Multiclonality Using Network Architectures Predicts Mechanism, Therapy, and Clinical Outcomes
Garry P. Nolan, Ph.D., Director, Stanford NHLBI Proteomics Center, Microbiology & Immunology, Stanford University 

Applying Broad Pathway Analysis and Deep Pathway Analysis to Biology and Medicine
Roger Brent, Ph.D., President and Research Director, Molecular Sciences Institute 

A Systems Approach to Breast Cancer Treatment
Joe W. Gray, Ph.D., Director, Life Sciences, Lawrence Berkeley National Laboratory

Additional Featured Speakers:

Genomic Analysis of Cancer with Next Generation DNA Sequencing Technologies
Robert L. Strausberg, Ph.D., Deputy Director, J. Craig Venter Institute

Genotype Wide Association Studies in Cancer
Stephen J. Chanock, M.D., Director, Core Genotyping Facility Section Head, Translational Genomics
Lab, National Cancer Institute 

Target Selection from DNA Copy Number and Expression Analyses of Breast and Ovarian Tumors
Zemin Zhang, Ph.D., Senior Scientist and Acting Director, Department of Bioinformatics, Genentech, Inc.

DNA Copy Number Variation and Cancer Susceptibility: Modifying the Two-Hit Hypothesis
David Malkin, M.D., Co-Director of the Cancer Genetics Program, University of Toronto's Hospital for Sick Children

microRNAs in Development and Cancer
Frank J. Slack, Ph.D., Associate Professor, Molecular Cellular & Developmental Biology, Yale University

Integrative Genomics and Epigenomics; Markers and Mechanisms
Joseph F. Costello, Ph.D., Associate Professor, Karen Osney Brownstein Endowed Chair in Molecular Neuro-Oncology, University of California San Francisco 

Computational Methods for Analysis of Cellular Functions and Pathways Collectively Targeted
by Differentially Expressed microRNA
Yuriy Gusev, Ph.D., Assistant Professor, Surgery & Adjunct Assistant Professor, Institute for Breast Health, University of Oklahoma

Epigenetic Silencing of the Intronic microRNA Mir-342 in Colorectal Cancer
Muneesh Tewari, M.D., Ph.D., Assistant Member, Human Biology Division, Fred Hutchinson Cancer Research Center

Diagnostic and Therapeutic microRNA Strategies in Ovarian Cancer 
Lin Zhang, Center for Research on Early Detection and Cure of Ovarian Cancer, University of Pennsylvania School of Medicine

Systems Optimization of ErbB-Targeted Therapeutics: Development of an Anti-ErbB3 Monoclonal Antibody
Ulrik B. Nielsen, Ph.D., Vice President, Research, Merrimack Pharmaceuticals 

Oncology Target-Disease Linkage through Pathway Profiling
Lihua Yu, Principal Scientist, Cancer Bioscience, AstraZeneca PLC 

Evaluation of Molecular Pathway Biomarkers of Novel Cancer Therapeutics
Sherry X. Yang, M.D., Ph.D, Chief of Nat'l Clinical Target Validation Laboratory, Division of Cancer Treatment and Diagnosis, National Cancer Institute

Epitomics: Individualized Immunoprofiling of Cancer-Specific Circulating Antibodies on Protein Microarrays of Tumor Associated Antigens
Michael A. Tainsky, Barbara & Fred Erb Professor of Cancer Genetics, Karmanos Cancer Institute, Department of Pathology, Wayne State University School of Medicine

Whole Genome Expression Profiling of Ovarian Cancer: Heading Toward Individualized Care
Michael Birrer, M.D., Ph.D., Deputy Branch Chief & Cell & Cancer Biology Head, Center for Cancer Research, National Cancer Institute

Personalized Cancer Therapy in the Light of Associative Learning: A Systematic Approach
to Remove Technical and Analytical Difficulties from its Path
Zoltan Szallasi, M.D., Senior Research Scientist, Children's Hospital, Boston, USA, Professor, Danish Technical University, Lyngby, Denmark 

An Approach to Understanding the Functional Consequences of Susceptibility Alleles Discovered In Genome Wide Association Scans  
Matthew Freedman M.D., Assistant Professor, Harvard Medical School, Associate Physician, Dana-Farber Cancer Institute, Associate Member, Broad Institute

 
Blood-based Colorectal Cancer Screening
Dr. Katja Bierau, Vice President, Laboratory Operations, R&D, OncoMethylome Sciences

Multi-Dimensional Pathways in Cancer
Michael Liebman, Ph.D., Managing Director, Strategic Medicine, Inc.

Expression Profiles for Individual Tumors: Systems Level Modeling and Pathway Analysis
Craig Giroux, Ph.D., Director of Systems and Computational Biology, Karmanos Cancer Institute, Wayne State University

Roadmap Toward Personalized Medicine
Craig Webb, Ph.D., Director, Program of Translational Medicine, Van Andel Research Institute

Cancer Pathways Analysis Through Inhibitor Profiling
Fei Hua, Ph.D., Senior Scientist, Systems Biology, Pfizer Inc.


Plenary Keynotes:

Brave New Age of Personalized Medicine
David Ewing Duncan, Chief Correspondent, NPR Talk's "Biotech Nation" and Best Selling Author "Masterminds"

Using Molecular Medicine to do Therapeutic Development in the Network Age
Jay M. Tenenbaum, Ph.D., Chairman and Chief Scientist, CollabRx, Inc. 

Tissue Engineering Strategies for Musculoskeletal Regenerative Medicine in Civilian and Military Applications
Michael J. Yaszemski, M.D., Ph.D., Brigadier General, United States Air Force, Professor, Orthopedic Surgery and Biomedical Engineering, Mayo Clinic College of Medicine

Engineering Cells to Death
James A. Wells, Ph.D., Professor and Chair of Pharmaceutical Chemistry, and Professor of Cellular & Molecular Pharmacology, University of California, San Francisco

Visit www.tri-conference.com/09_gdd.asp for complete details on these presentations along with speaker biographies.

Participate in these Breakout Discussions:

Taking Account of the Limitations of Biomarker Discovery in Cancer
Moderator: Zoltan Szallasi, M.D., Senior Research Scientist, Children's Hospital, Boston, USA, Professor, Danish Technical Uiniversity, Lyngby, Denmark

  • Are we ready to face the limitations of genome scale screening based biomarker discovery?
  • Worst and best case scenarios: the variables are not independent and this should give us cautious hope if we know how to take advantage of it 
  • Can we optimize the efficiency of genome scale screening based biomarker discovery in cancer technical and cohort design related issues

DNA Copy Number Variation and Cancer Susceptibility
Moderator: David Malkin, M.D., Co-Director of the Cancer Genetics Program, University of Toronto's Hospital for Sick Children 

  • How can DNA Copy Number variation be used to enhance molecular profiling of cancer susceptibility?
  • What genetic mechanisms explain the development of copy number variable regions of DNA?
  • What is the relationship of copy number variable regions and specific target 'cancer genes' in the carcinogenic process?

Epigenetics and MicroRNA
Moderators: Dalia Cohen, Ph.D., Chief Scientific Officer, Rosetta Genomics Inc. and Enal Razvi, Ph.D., System Biosciences SBI 

  • Role of epigenetics and microRNAs in cancer and differentiation-exploring the connections
  • Impact of epigenetics and microRNA on the expanding stem cells research and regenerative medicine efforts
  • How to commercialize upon the microRNA space?
  • What about epigenetics? The current landscape and what value it offers for diagnostics/therapeutics in the future

Expression Profiles for Individual Tumors
Moderator: Craig N. Giroux, Ph.D., Associate Professor, Research, Karmanos Cancer Institute, Wayne State University

  • How can we best use static snapshots (gene signatures) of a moving target (dynamic tumor progression) to guide cancer treatment?
  • How do we deal with tumor heterogeneity and its confounding effects on our ability to distinguish driver from passenger effects in tumor progression?
  • Can we define an individual tumor expression profile (private variation) or must we settle for a sub-type classification (common variation)?
  • How do we score a gene expression signature: statistical metrics or network topology?

Don't Miss the Pre-Conference Short Course

CIRCULATING TUMOR CELLS AND CANCER STEM CELLS

Topics to be covered:

  • CTC specific biomarkers and clinical applications
  • Advanced CTC and Cancer Stem Cell enrichment, detection and downstream analyses technologies
  • Stem Cell technologies  

 Course Instructors:

 John Park, M.D., Associate Clinical Professor, Hematology & Oncology, University of California,  San Francisco
 
 Glenn Deng, Ph.D., Senior Scientist, Circulating Tumor Cells, Genetix
 
 Katharina Effenberger, Ph.D., Institute of Tumor Biology, Center for Experimental Medicine,  University Medical Center Hamburg-Eppendorf

 Amir Ali Talasaz, Ph.D., Research Associate, Stanford Genome Technology Center, Stanford  University
 
 Ying Liu, Ph.D., M.D., Stem Cells and Regenerative Medicine, Invitrogen  

Massimo Cristofanilli, M.D., The University of Texas, MD Anderson Cancer Center

 Click Here to View the Entire List of Pre-Conferences

Cancer Profiling and Pathways
is Part of the 16th International Molecular Medicine Tri-Conference

February 25-27, 2009
San Francisco, California

www.tri-conference.com/09_gdd.asp